Neuphoria Therapeutics Inc.
For the period ended Mar 31, 2025. Filed May 20, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 20, 2025
NEUP$2.69-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Nine Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $8,514,025 | $(12,805,140) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation | 65,505 | 707,092 |
| Depreciation and amortization expense | 497,265 | 497,306 |
| Non-cash rent expense | 91,762 | 88,609 |
| Change in fair value of accompanying warrant liability | (2,770,375) | - |
| Change in fair value of contingent consideration | 66,937 | 584,299 |
| Effect of foreign currency remeasurement | (633,539) | 59,898 |
| Changes in assets and liabilities: | ||
| Accounts receivable, non-trade | 102,292 | 320,380 |
| Prepaid insurance expense | 437,868 | 164,273 |
| Accounts payable | (1,498,326) | (858,952) |
| Accrued expenses and other current liabilities | (778,432) | (221,054) |
| Operating lease liabilities | (98,558) | (88,801) |
| Deferred tax liability | (201,803) | (104,380) |
| Contingent consideration | (133,080) | - |
| Other non-current liabilities | 761 | (13,517) |
| Net cash provided by (used in) operating activities | 3,662,302 | (11,669,987) |
| Cash flows from financing activities: | ||
| Proceeds from the sale of equity, net of issuance costs of $0.4 million | 823,601 | - |
| Proceeds from the sale of equity, net of issuance costs of $0.9 million | - | 7,987,228 |
| Net cash provided by financing activities | 823,601 | 7,987,228 |
| Effect of exchange rate on changes on cash, cash equivalents, and restricted cash | (53,356) | 4,607 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 4,432,547 | (3,678,152) |
| Cash, cash equivalents, and restricted cash, beginning of period | 12,686,935 | 12,181,944 |
| Cash, cash equivalents, and restricted cash, end of period | $17,119,482 | $8,503,792 |
| Reconciliation of cash, cash equivalents, and restricted cash: | ||
| Cash and cash equivalents | $17,044,750 | $8,426,061 |
| Restricted cash | 74,732 | 77,731 |
| Total cash, cash equivalents, and restricted cash | $17,119,482 | $8,503,792 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.